Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramin Tadayoni

Showing results (191-200 of 212) with videos related to

Pageof 22
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|January 31, 2016
Treatment of Uveitis by In Situ Administration of Ex Vivo-Activated Polyclonal Regulatory T CellsSylvie Grégoire, Céline Terrada, Gaelle H Martin, et al.
European Journal of Ophthalmology|February 17, 2022
Incidence and characteristics of rhegmatogenous retinal detachment during coronavirus-19 pandemic: A French studyAgathe Vest, Chafik Keilani, Philippe Chaumet-Riffaud, et al.
Ophthalmology|January 27, 2024
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO TrialsRamin Tadayoni, Liliana P Paris, Carl J Danzig, et al.
Lancet (London, England)|January 27, 2022
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trialsCharles C Wykoff, Francis Abreu, Anthony P Adamis, et al.
American Journal of Ophthalmology|January 17, 2022
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular EdemaDavid M Brown, Andrés Emanuelli, Francesco Bandello, et al.
Ophthalmology Science|February 5, 2024
Imaging Modalities for Assessing the Vascular Component of Diabetic Retinal Disease: Review and Consensus for an Updated Staging SystemTien-En Tan, Lee M Jampol, Frederick L Ferris, et al.
Ophthalmology. Retina|September 24, 2023
Natural History and Surgical Outcomes of Lamellar Macular HolesIsmael Chehaibou, Ramin Tadayoni, Jean-Pierre Hubschman, et al.
Pharmaceutics|February 4, 2021
Visual Acuity Gain Profiles and Anatomical Prognosis Factors in Patients with Drug-Naive Diabetic Macular Edema Treated with Dexamethasone Implant: The NAVEDEX StudyMauricio Pinto, Thibaud Mathis, Pascale Massin, et al.
Ophthalmology|February 21, 2024
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2Arshad M Khanani, Aachal Kotecha, Andrew Chang, et al.
Lancet (London, England)|September 11, 2023
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trialArshad M Khanani, Sunil S Patel, Giovanni Staurenghi, et al.
Pageof 22

Showing results (191-200 of 212) with videos related to

Sort By:
Pageof 22
Journal of Immunology (Baltimore, Md. : 1950)|January 31, 2016
Treatment of Uveitis by In Situ Administration of Ex Vivo-Activated Polyclonal Regulatory T CellsSylvie Grégoire, Céline Terrada, Gaelle H Martin, et al.
European Journal of Ophthalmology|February 17, 2022
Incidence and characteristics of rhegmatogenous retinal detachment during coronavirus-19 pandemic: A French studyAgathe Vest, Chafik Keilani, Philippe Chaumet-Riffaud, et al.
Ophthalmology|January 27, 2024
Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO TrialsRamin Tadayoni, Liliana P Paris, Carl J Danzig, et al.
Lancet (London, England)|January 27, 2022
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trialsCharles C Wykoff, Francis Abreu, Anthony P Adamis, et al.
American Journal of Ophthalmology|January 17, 2022
KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular EdemaDavid M Brown, Andrés Emanuelli, Francesco Bandello, et al.
Ophthalmology Science|February 5, 2024
Imaging Modalities for Assessing the Vascular Component of Diabetic Retinal Disease: Review and Consensus for an Updated Staging SystemTien-En Tan, Lee M Jampol, Frederick L Ferris, et al.
Ophthalmology. Retina|September 24, 2023
Natural History and Surgical Outcomes of Lamellar Macular HolesIsmael Chehaibou, Ramin Tadayoni, Jean-Pierre Hubschman, et al.
Pharmaceutics|February 4, 2021
Visual Acuity Gain Profiles and Anatomical Prognosis Factors in Patients with Drug-Naive Diabetic Macular Edema Treated with Dexamethasone Implant: The NAVEDEX StudyMauricio Pinto, Thibaud Mathis, Pascale Massin, et al.
Ophthalmology|February 21, 2024
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2Arshad M Khanani, Aachal Kotecha, Andrew Chang, et al.
Lancet (London, England)|September 11, 2023
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trialArshad M Khanani, Sunil S Patel, Giovanni Staurenghi, et al.
Pageof 22